Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYQCWT)

Drug Name
Tecartus Drug Info
Synonyms Brexucabtagene autoleucel; KTE-X19
Indication
Disease Entry ICD 11 Status REF
Mantle cell lymphoma 2A85.5 Approved [1]
Cross-matching ID
TTD Drug ID
DMYQCWT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [2]
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [3]
Axicabtagene ciloleucel DMYHN59 Diffuse large B-cell lymphoma 2A81 Approved [4]
Lisocabtagene maraleucel DMP45ME Large B-cell lymphoma 2A81 Approved [5]
Inebilizumab DMI0RHA Neuromyelitis optica spectrum disorder 8E4A.0 Approved [6]
Loncastuximab tesirine DMXSVGI Diffuse large B-cell lymphoma 2A81 Approved [7]
Obexelimab DMVIC4J IgG4 related disease 4A43.0 Phase 3 [8]
MOR-208 DMDQOWT Diffuse large B-cell lymphoma 2A81 Phase 2/3 [9]
CART-19 DMST3FM Acute lymphoblastic leukaemia 2A85 Phase 2/3 [10]
CD19 CAR T cells DM32148 Acute lymphoblastic leukaemia 2A85 Phase 2/3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Not Available [1]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
8 Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
9 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
10 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
11 ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma